核心观点公司25H1 海外市场隐形矫治器收入约为7170 万美元，同比+123.4%；达成案例数11.72 万例，同比+103.5%，首次超过国内市场案例数。海外分部经营亏损由去年同期的1670 万美元大幅收窄至540 万美元，主要是因为业务规模扩大，以及延缓了海外的医学设计中心、生产基地的运营，暂缓若干区域相关人员招募。25H1 海外市场案例数的高速增长反映了公司全球化战略的初步成功，未来将会...
Source Link核心观点公司25H1 海外市场隐形矫治器收入约为7170 万美元，同比+123.4%；达成案例数11.72 万例，同比+103.5%，首次超过国内市场案例数。海外分部经营亏损由去年同期的1670 万美元大幅收窄至540 万美元，主要是因为业务规模扩大，以及延缓了海外的医学设计中心、生产基地的运营，暂缓若干区域相关人员招募。25H1 海外市场案例数的高速增长反映了公司全球化战略的初步成功，未来将会...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.